Herbal Monograph
Horse chestnut
Aesculus hippocastanum L.
Sapindaceae (formerly Hippocastanaceae)
Premier venotonic herb for chronic venous insufficiency, varicose veins, and ...
Overview
Plant Description
Large deciduous tree, 20-40 m tall with a broad, domed crown up to 20 m in spread. Bark is grey-brown, smooth when young, becoming scaly and fissured with age. Branches are stout, spreading, with large sticky resinous buds (up to 3.5 cm long) in winter. Leaves are opposite, palmately compound with 5-7 obovate leaflets (10-25 cm long), each with a doubly serrate margin, dark green above and slightly pubescent on the veins beneath. Inflorescence is an erect, showy terminal panicle (candle), 15-30 cm long, bearing 20-50 white flowers with yellow blotch at the base of the petals that turns red after pollination (a signal to pollinators). Fruit is a large, spiny green capsule (husk), 4-6 cm in diameter, splitting into 2-3 valves to release 1-3 large, glossy reddish-brown seeds (conkers), 2-4 cm across, with a large, pale grey-white basal scar (hilum). Taproot system initially, developing lateral roots with age. Trees may live 250-300 years.
Habitat
Prefers deep, moist, well-drained, fertile soils in full sun to partial shade. Tolerates a wide range of soil pH (5.0-7.5) but performs best on slightly acidic to neutral loams. Moderately drought-tolerant once established but susceptible to leaf scorch in prolonged dry periods. Hardy to USDA zones 3-8. Grows best in cool temperate climates with adequate rainfall. Often found along riverbanks, in mixed deciduous forests, and in ravines at elevations of 500-1500 m in its native range.
Distribution
Native to a small area of the Balkan Peninsula (northern Greece, Albania, North Macedonia, and Bulgaria), particularly in the Pindus Mountains and mountains of northern Greece. Introduced to central and western Europe in the late 16th century (first recorded cultivation in Vienna, 1576; England, 1616). Now widely planted and naturalized throughout Europe, the British Isles, North America, and temperate regions worldwide as a shade and ornamental tree. Extensively cultivated in Germany, Poland, and other central European countries for both ornamental and pharmaceutical purposes.
Parts Used
Seed extract (Hippocastani semen — processed, standardized extract ONLY)
Preferred: Standardized dry extract (HCSE) in delayed-release capsules or tablets; topical gel preparations containing aescin
The seed is the official drug part in all major pharmacopeias and regulatory monographs (Commission E, WHO, EMA/HMPC, European Pharmacopoeia). CRITICAL: Only processed, standardized horse chestnut seed extract (HCSE) with esculin removed is safe for internal use. Raw, unprocessed seeds contain the toxic coumarin glycoside esculin and are poisonous — ingestion of raw seeds has caused deaths, particularly in children. The standardized extract is produced using ethanol (40-80% v/v) and adjusted to contain 16-20% triterpene glycosides (calculated as anhydrous aescin) per the Commission E monograph, or 6.5-10% triterpene glycosides (calculated as protoaescigenin) per the EMA well-established use monograph.
Bark (Hippocastani cortex)
Preferred: Decoction for external wash or compress; ointment
Young branch bark has a separate EMA traditional use monograph for topical application and symptomatic relief of minor venous circulatory disturbances. Contains coumarins (esculin, aesculetin, fraxin), tannins, and flavonoids. Used primarily in traditional European herbalism as a topical astringent. Less clinically studied than seed extract. The Commission E monograph for bark is separate from the seed monograph.
Key Constituents
Triterpene saponins (aescin / escin)
Aescin (escin) is the primary active constituent responsible for virtually all of horse chestnut's clinically demonstrated effects in chronic venous insufficiency. Mechanism of action: (1) Reduces capillary permeability by inhibiting degradation of the capillary wall glycocalyx via inhibition of lysosomal enzymes (elastase, hyaluronidase); (2) Increases venous tone via stimulation of prostaglandin F2-alpha (PGF2a) production in venous smooth muscle; (3) Anti-edematous activity through reduction of transcapillary filtration; (4) Anti-inflammatory activity via inhibition of phospholipase A2, modulation of NF-kB signaling, and reduction of pro-inflammatory cytokines. The EMA well-established use monograph and the Cochrane review both identify aescin as the therapeutically relevant marker compound.
Coumarins and coumarin glycosides
The coumarin fraction is paradoxically both the source of raw seed toxicity (esculin) and a contributor to the bark's traditional topical anti-inflammatory use (aesculetin). In properly manufactured HCSE, the coumarins are removed. The presence of esculin is the primary reason raw seeds are toxic and why AHPA classifies horse chestnut seed as Class 2d — requiring specific processing (standardized extract only) for safe use. The bark contains significant coumarins and tannins that contribute to its traditional topical astringent and anti-inflammatory application.
Flavonoids
The flavonoid fraction contributes supportive antioxidant and capillary-stabilizing activity that complements the primary venotonic action of aescin. Rutin in particular is a well-established capillary protectant. However, the flavonoid content of HCSE is secondary to aescin in terms of clinical significance for chronic venous insufficiency.
Proanthocyanidins (condensed tannins)
Proanthocyanidins are well-established capillary protectants and antioxidants. In horse chestnut, they contribute secondary vascular-protective and astringent effects. Their role is considered ancillary to the primary activity of aescin saponins in the standardized extract.
Other constituents
Minor constituents providing ancillary effects. Allantoin is the most therapeutically interesting of these, contributing to topical wound-healing and skin-soothing effects in gel and cream formulations. Phytosterols may provide mild anti-inflammatory support.
Herbal Actions
The principal and most clinically validated action of horse chestnut seed extract. Aescin increases venous tone and contractility by sensitizing venous smooth muscle to calcium ions and stimulating prostaglandin F2-alpha (PGF2a) release, which causes venoconstriction. This improves venous return and reduces venous pooling. Commission E approved for chronic venous insufficiency based on this action. The EMA well-established use monograph recognizes HCSE for CVI treatment. The Cochrane review (Pittler & Ernst, 2012) confirmed efficacy for CVI symptoms across 17 RCTs.
[1, 3, 6, 10]Reduces peripheral edema, particularly in the lower extremities, by decreasing transcapillary filtration. Aescin inhibits lysosomal enzymes (hyaluronidase, elastase) that break down proteoglycans in the capillary endothelium, thereby reducing capillary permeability and preventing fluid extravasation into the interstitial space. The Cochrane review meta-analysis of 5 trials showed a significant mean reduction in lower leg volume of 56.3 mL (95% CI 24.1-88.5) compared to placebo.
[1, 10, 12]Reduces inflammation
Aescin demonstrates anti-inflammatory activity through multiple mechanisms: inhibition of phospholipase A2, modulation of NF-kB signaling, reduction of pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6), and inhibition of complement activation. Clinically relevant for reducing pain, heaviness, and discomfort in CVI. Also contributes to the use in hemorrhoidal symptoms.
[1, 6, 12]Protects capillary wall integrity by inhibiting degradation of the endothelial glycocalyx. Aescin inhibits hyaluronidase and other lysosomal enzymes responsible for the breakdown of proteoglycans in the capillary wall, thereby maintaining normal capillary permeability and preventing excessive fluid leakage. This action underlies the anti-edematous effect and is a key mechanism in CVI treatment.
[1, 2, 12]Tightens and tones tissue, reduces secretions
Contributed primarily by the tannin and proanthocyanidin fraction. More relevant to bark preparations used topically. The astringent action tightens and tones tissues, reducing excessive secretions. In the context of venous health, the astringent quality complements the venotonic effect by supporting connective tissue tone in vein walls.
[5, 6]Prevents or slows oxidative damage to cells
Contributed by the flavonoid and proanthocyanidin fractions. Reduces oxidative stress in venous endothelium, which is a contributor to venous wall damage in CVI. The antioxidant activity is considered supportive rather than primary.
[6]Therapeutic Indications
cardiovascular-venous
Chronic venous insufficiency (CVI)
Commission E approved indication. WHO monograph indication. EMA well-established use monograph indication. The primary and best-supported therapeutic use of HCSE. The Cochrane systematic review (Pittler & Ernst, 2012) analyzed 17 RCTs and concluded HCSE is an efficacious and safe short-term treatment for CVI. Symptoms improved include leg pain, edema, pruritus, heaviness, and fatigue. HCSE has been compared favorably to compression therapy in some trials. Standardized extract (equivalent to 100-150 mg aescin daily) is the required form.
[1, 2, 3, 10]Varicose veins (symptoms)
Symptomatic relief of pain, heaviness, leg fatigue, and swelling associated with varicose veins. HCSE does not reverse the structural damage to venous valves but improves subjective symptoms and reduces edema. Supported by multiple RCTs included in the Cochrane review. Commission E indication.
[1, 5, 10]Lower leg edema associated with venous insufficiency
The anti-edematous effect is one of the most robustly demonstrated outcomes. Cochrane review meta-analysis of 5 trials (n=289) found a significant reduction in leg volume (WMD 56.3 mL, 95% CI 24.1-88.5) with HCSE versus placebo. Diuretic activity is not the mechanism — aescin reduces edema by decreasing capillary permeability.
[1, 3, 10]cardiovascular-venous (anorectal)
Hemorrhoids (symptomatic relief)
One double-blind, placebo-controlled trial of 80 patients found aescin (40 mg three times daily) improved pain, bleeding, and swelling within one week. The venotonic and anti-inflammatory mechanisms are pharmacologically relevant to hemorrhoidal veins. Traditional use is well documented. However, evidence is more limited than for CVI; Memorial Sloan Kettering notes the evidence base is not yet definitive. Mills & Bone include hemorrhoids as an indication based on the shared venotropic mechanism.
[5, 6, 12]Musculoskeletal System
Post-traumatic and post-operative edema
Intravenous aescin has been used in European hospital settings for post-surgical and post-traumatic swelling. Oral HCSE has also been used. Several clinical trials have shown benefit in reducing post-operative edema, particularly after orthopedic and plastic surgery. The anti-edematous and anti-inflammatory actions provide pharmacological rationale.
[2, 12]Sports injuries with soft tissue swelling (topical)
EMA traditional use monograph includes topical application for relief of signs of bruises, such as local swelling and hematoma. Topical aescin gel (2%) is used in European sports medicine for contusions and sprains. Evidence is primarily from traditional use and small studies.
[3]Skin / Integumentary
Leg heaviness and discomfort related to minor venous circulatory disturbances
EMA traditional use monograph indication for oral and topical use. Characterized by feelings of heaviness, tension, tiredness, and aching in the legs. The venotonic and anti-edematous actions improve venous return and reduce interstitial fluid accumulation.
[1, 3]Energetics
Temperature
cool
Moisture
dry
Taste
Tissue States
damp/stagnation, lax/atony, heat/excitation
In Western energetic assessment, horse chestnut is cooling and drying. Its pronounced bitterness and astringency reflect the saponin and tannin content respectively. The cooling quality addresses the heat and inflammation of congested, engorged veins. The drying and astringent quality counters the damp, boggy tissue state seen in venous insufficiency — swollen, waterlogged tissues with poor tone. Indicated for lax, atonic vascular tissue with fluid accumulation. Hoffmann and Mills & Bone both emphasize horse chestnut's specificity for conditions involving venous congestion with edema and tissue laxity.
Traditional Uses
European traditional herbalism
- Treatment of varicose veins and venous congestion in the lower extremities
- Hemorrhoids and anorectal venous congestion
- Leg swelling and edema
- Topical poultice for swollen joints and bruising
- Bark decoction as astringent wash for leg ulcers
"Hoffmann (2003): 'Horse chestnut is one of the most important herbs for the treatment of problems related to poor venous circulation... The seeds are the source of a preparation that has been extensively studied and shown to be of benefit in chronic venous insufficiency. It has a specific action on the venous system, reducing vein wall permeability and increasing venous tone.' Mills & Bone (2013) classify horse chestnut as a venotropic agent indicated for chronic venous insufficiency, varicose veins, and hemorrhoids."
Balkan and southeastern European folk medicine
- Seed poultices applied to swollen legs and hemorrhoids
- Bark decoctions for diarrhea and dysentery (astringent)
- Topical applications for leg ulcers and chronic wounds
- Seeds carried as a folk remedy for rheumatism and back pain
"In the Balkan region, where A. hippocastanum is native, seeds were traditionally used as poultices for swollen legs, hemorrhoids, and leg ulcers. Bark decoctions served as astringent remedies for gastrointestinal complaints. Grieve (A Modern Herbal, 1931): the name Hippocastanum may derive from 'its ability to cure cattle and horses of broken-windedness and coughs.' Grieve documented that crushed nuts, leaves, and bark 'eased the pain and inflammation of hemorrhoids and soothed achiness and weariness in the legs.'"
[13]
German phytotherapy (Commission E / ESCOP)
- Chronic venous insufficiency including pain, heaviness, and swelling in the legs
- Varicose veins (symptomatic treatment)
- Nocturnal leg cramps associated with venous insufficiency
"The German Commission E approved horse chestnut seed extract for 'complaints found in pathological conditions of the veins of the legs (chronic venous insufficiency), for example, pains and heaviness in the legs, nocturnal cramps in the calves, itching and swelling of the legs.' The Commission E specifies standardized dry extract adjusted to 16-20% triterpene glycosides (calculated as anhydrous aescin) at a dose equivalent to 100 mg aescin daily, with a maintenance dose of 35-70 mg aescin daily. ESCOP monograph extends the indication to 'treatment of symptoms of chronic venous insufficiency and varicose veins.'"
British Herbal Pharmacopoeia / British herbalism
- Varicose veins
- Hemorrhoids
- Phlebitis (adjunctive)
"The British Herbal Pharmacopoeia lists Aesculus hippocastanum for varicose veins and hemorrhoids. The British herbal tradition emphasizes the venotonic and astringent actions of both the seed extract and bark preparations."
[8]
Modern Research
Chronic venous insufficiency — Cochrane systematic review
Cochrane systematic review of horse chestnut seed extract (HCSE) for chronic venous insufficiency (CVI), the most comprehensive evidence synthesis available.
Findings: Pittler & Ernst (2012) conducted a Cochrane systematic review including 17 randomized controlled trials of oral HCSE for CVI. All trials used extract standardized to aescin. Key findings: (1) Leg pain: Six trials assessed leg pain; five found statistically significant improvements with HCSE versus placebo. (2) Leg volume/edema: Meta-analysis of 5 trials (n=289) showed a significant mean reduction in leg volume of 56.3 mL (95% CI 24.1-88.5) favoring HCSE. (3) Pruritus: Four trials reported improvement in itching with HCSE. (4) Leg fatigue/heaviness: Significant improvement compared to placebo in multiple trials. (5) Adverse events: Frequency ranged from 0.9% to 3.0% across 8 studies, including GI complaints, headache, dizziness, and pruritus. In 3 studies, adverse event rates were not significantly different from placebo. The review concluded: 'The evidence presented suggests that HCSE is an efficacious and safe short-term treatment for CVI.'
Limitations: Several caveats identified: most trials were of short duration (2-16 weeks), methodological quality was variable with several trials at unclear or high risk of bias, and larger definitive RCTs were called for to confirm efficacy. Long-term efficacy and safety data are limited. The reviewers noted a need for studies with longer follow-up and comparison against active treatments such as compression stockings.
[10]
Comparison with compression therapy
Clinical trial comparing HCSE with compression stockings for CVI-related edema.
Findings: Diehm et al. (1996) conducted a randomized, partially blinded study comparing HCSE (standardized to 50 mg aescin twice daily), compression stockings, and placebo in 240 patients with CVI-related lower leg edema over 12 weeks. Both HCSE and compression stockings significantly reduced lower leg volume compared to placebo (HCSE: -43.8 mL; compression: -46.7 mL). The reduction in leg volume was comparable between HCSE and compression, suggesting HCSE may be an alternative for patients unable to tolerate compression therapy.
Limitations: Partially blinded design (compression stockings could not be blinded). Single-center study. 12-week duration. HCSE is not a structural treatment for venous valve incompetence and does not replace compression in severe CVI.
[11]
Aescin pharmacology — mechanism of action
Comprehensive review of the pharmacological, pharmacokinetic, and therapeutic profile of aescin.
Findings: Sirtori (2001) reviewed the pharmacology of aescin. Key mechanisms: (1) Anti-edematous: Aescin inhibits lysosomal enzymes (hyaluronidase, elastase, beta-glucuronidase) that degrade proteoglycans in the venous capillary endothelium, thereby reducing capillary permeability. (2) Venotonic: Aescin sensitizes venous smooth muscle to calcium ions and stimulates PGF2-alpha release, causing venoconstriction and improved venous return. (3) Anti-inflammatory: Inhibits phospholipase A2 and reduces production of inflammatory prostaglandins. (4) Pharmacokinetics: Oral bioavailability of aescin is relatively low (~5%) but improved by delayed-release formulations; peak plasma levels at 2-3 hours; elimination half-life approximately 20 hours.
Limitations: Narrative review synthesizing preclinical and clinical data. Some pharmacokinetic data from older studies with less rigorous methodology. Dose-response relationships in humans are not fully characterized.
[12]
Anti-inflammatory activity of aescin
Evaluation of anti-inflammatory and anti-cancer properties of beta-escin as a triterpene saponin.
Findings: Multiple in vitro and in vivo studies have demonstrated that beta-aescin inhibits NF-kB activation, reduces TNF-alpha, IL-1-beta, and IL-6 production, and inhibits leukocyte adhesion to endothelial cells. Anti-inflammatory activity has been confirmed in carrageenan paw edema, cotton pellet granuloma, and other experimental models. The anti-inflammatory mechanism involves modulation of eicosanoid production via phospholipase A2 inhibition and NF-kB signaling suppression.
Limitations: Much of the anti-inflammatory evidence is from in vitro and animal studies. Direct extrapolation to human clinical outcomes requires caution. The anti-inflammatory contribution of aescin to CVI symptom relief (as opposed to the venotonic and anti-edematous effects) has not been isolated in clinical trials.
[12]
Post-marketing surveillance safety data
Large-scale post-marketing safety monitoring of HCSE in clinical practice.
Findings: Post-marketing surveillance studies involving over 6,000 patients treated with HCSE reported adverse events in 43 of 6,183 patients (0.7%), including pruritus, nausea, gastrointestinal complaints, headache, and dizziness. A separate observational study of 5,000 patients found adverse events in 0.6%. Adverse effects were predominantly mild and self-limiting. No serious adverse events were reported at standard oral doses of standardized extract.
Limitations: Post-marketing surveillance is subject to reporting bias and underreporting. Long-term safety beyond 12-16 weeks is less well characterized. These data apply only to properly standardized HCSE with esculin removed, not to raw or non-standardized preparations.
Preparations & Dosage
Standardized Extract
Strength: Standardized to 16-20% triterpene glycosides calculated as anhydrous aescin (Commission E standard); or 6.5-10% triterpene glycosides calculated as protoaescigenin (EMA standard). Typical product: 300 mg extract = 50 mg aescin per capsule.
Horse chestnut seed extract (HCSE) is manufactured commercially by specialized pharmaceutical processes. The dried seeds are extracted with ethanol (40-80% v/v), purified to remove the toxic coumarin glycoside esculin, and standardized to contain 16-20% triterpene glycosides (calculated as anhydrous aescin per the Commission E monograph) or 6.5-10% triterpene glycosides (calculated as protoaescigenin per the EMA monograph). The extract is formulated into delayed-release (enteric-coated) capsules or tablets to minimize gastrointestinal irritation and improve bioavailability. ONLY commercially prepared, standardized extract with esculin removed should be used. Do NOT attempt to prepare extracts from raw seeds.
300 mg standardized extract (equivalent to 50 mg aescin) twice daily, or 600 mg daily in divided doses. Commission E: initial dose equivalent to 100 mg aescin daily (approximately 500-600 mg extract), reducing to a maintenance dose of 35-70 mg aescin daily
Twice daily (morning and evening), taken with meals to minimize GI irritation
Clinical trials have typically used 2-16 weeks. Commission E does not specify a maximum duration. EMA well-established use monograph: if symptoms persist beyond 2 weeks during use, a doctor should be consulted. Long-term use beyond 12 weeks should be under practitioner supervision.
Not recommended for children under 18 years due to insufficient safety data. The EMA monograph states use in children and adolescents under 18 is not recommended.
This is the ONLY appropriate internal preparation. Raw seeds, teas, infusions, or tinctures made from unprocessed horse chestnut seeds must NOT be used internally due to esculin toxicity. Delayed-release (enteric-coated) formulations are preferred to reduce gastrointestinal side effects and improve aescin bioavailability. The most studied commercial preparation is Venostasin (Klinge Pharma), standardized to 50 mg aescin per delayed-release capsule.
topical
Strength: 2% aescin in gel or cream base (standard concentration in commercial topical products)
Topical gel or cream containing 2% aescin applied to the affected area. Commercial preparations are available as gels, creams, and ointments. Apply to intact skin only — do not apply to broken skin, open wounds, or mucous membranes. Gently massage into the skin of the affected area.
Apply a thin layer to the affected area 2-3 times daily
2-3 times daily
As needed for symptom relief; consult a practitioner if symptoms persist beyond 2 weeks
Not recommended under 18 years due to insufficient data
EMA traditional use monograph includes topical application for 'relief of signs of bruises, such as local swelling and hematoma' and for 'discomfort and heaviness of legs related to minor venous circulatory disturbances.' Topical preparations provide local anti-inflammatory and anti-edematous effects. Skin penetration of aescin is enhanced in gel formulations. Do not apply to broken skin or near the eyes.
[3]
Safety & Interactions
Class 2d
Other specific use restrictions apply (AHPA Botanical Safety Handbook)
Contraindications
Raw horse chestnut seeds contain the toxic coumarin glycoside esculin, which causes severe poisoning. Symptoms include intense gastrointestinal distress (nausea, vomiting, diarrhea), muscle twitching, weakness, loss of coordination, dilated pupils, paralysis, and potentially death. Deaths have been reported, particularly in children, from ingestion of raw seeds. As little as 1% of a child's body weight in raw seed material may be lethal. ONLY commercially prepared, standardized horse chestnut seed extract (HCSE) with esculin removed is safe for oral use. AHPA Class 2d: 'Not to be used except in dosage forms that are processed to remove esculin.'
Horse chestnut seed extract is contraindicated in patients with renal impairment. Reports exist of worsening kidney function in patients with pre-existing kidney disease who received aescin (particularly intravenous aescin). Aescin may be nephrotoxic in patients with compromised renal function. Avoid use in any degree of renal impairment.
Horse chestnut seed extract should be avoided in patients with liver disease. Rare cases of clinically apparent liver injury have been reported with HCSE use. Impaired hepatic metabolism may increase systemic exposure to aescin and risk of hepatotoxicity.
Allergic reactions to horse chestnut preparations have been reported, including contact dermatitis with topical use and anaphylaxis (rare) with oral or parenteral administration. Discontinue use if allergic symptoms develop.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Warfarin and other anticoagulants (heparin, enoxaparin, dabigatran, rivaroxaban) (Anticoagulants) | theoretical | Aescin may have antiplatelet activity. Raw horse chestnut contains esculin, which has antithrombotic properties. Although esculin is removed from standardized HCSE, a potential for additive anticoagulant effect exists. Aescin may also bind to plasma proteins, potentially displacing warfarin from protein binding sites and increasing free warfarin levels. |
| Antiplatelet agents (aspirin, clopidogrel, ticagrelor) (Antiplatelet drugs) | theoretical | Potential additive inhibition of platelet aggregation. Mechanism not fully characterized but relates to aescin's effects on prostaglandin metabolism. |
| Insulin and oral hypoglycemic agents (metformin, sulfonylureas, GLP-1 agonists) (Antidiabetic drugs) | theoretical | Aescin may lower blood glucose levels. The mechanism is not fully characterized but may involve enhanced insulin sensitivity or effects on hepatic glucose output. |
| NSAIDs (ibuprofen, naproxen, diclofenac) (Non-steroidal anti-inflammatory drugs) | theoretical | Potential additive effects on platelet function and GI mucosa irritation. Both NSAIDs and aescin affect prostaglandin metabolism. |
Pregnancy & Lactation
Pregnancy
insufficient data
Lactation
insufficient data
Safety of HCSE during pregnancy and lactation has not been established. The EMA monograph states: 'In the absence of sufficient data, the use in pregnancy and lactation is not recommended.' There are no adequate and well-controlled studies in pregnant women. Although some older references note no evidence of teratogenicity, the data are insufficient to confirm safety. Raw horse chestnut seeds are toxic and must never be consumed during pregnancy. The WHO monograph also advises against use during pregnancy and lactation. As a general precaution, HCSE should be avoided during pregnancy and lactation unless the potential benefit justifies the potential risk and only under direct medical supervision.
Adverse Effects
References
Monograph Sources
- [1] Blumenthal, M., Busse, W.R., Goldberg, A., et al.. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council / Integrative Medicine Communications (1998) . ISBN: 978-0965555500
- [2] World Health Organization. WHO Monographs on Selected Medicinal Plants — Volume 2: Semen Hippocastani. World Health Organization, Geneva (1999) . ISBN: 978-9241545372
- [3] Committee on Herbal Medicinal Products (HMPC). European Union herbal monograph on Aesculus hippocastanum L., semen (Revision 1). European Medicines Agency (2020)
- [4] ESCOP (European Scientific Cooperative on Phytotherapy). ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products — Hippocastani semen (Horse Chestnut Seed). ESCOP / Thieme (2003) . ISBN: 978-1901964073
- [5] Hoffmann, D.. Medical Herbalism: The Science and Practice of Herbal Medicine. Healing Arts Press (2003) . ISBN: 978-0892817498
- [6] Mills, S., Bone, K.. Principles and Practice of Phytotherapy: Modern Herbal Medicine (2nd edition). Churchill Livingstone / Elsevier (2013) . ISBN: 978-0443069925
- [7] Gardner, Z., McGuffin, M. (eds.). American Herbal Products Association's Botanical Safety Handbook (2nd edition). CRC Press (2013) . ISBN: 978-1466516946
- [8] British Herbal Medicine Association. British Herbal Pharmacopoeia. BHMA (1983)
- [9] Brinker, F.. Herbal Contraindications and Drug Interactions (4th edition). Eclectic Medical Publications (2010) . ISBN: 978-1888483147
Clinical Studies
- [10] Pittler, M.H., Ernst, E.. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database of Systematic Reviews (2012) ; 11 : CD003230 . DOI: 10.1002/14651858.CD003230.pub4 . PMID: 23152216
- [11] Diehm, C., Trampisch, H.J., Lange, S., Schmidt, C.. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. The Lancet (1996) ; 347 : 292-294 . DOI: 10.1016/S0140-6736(96)90467-5 . PMID: 8569363
- [12] Sirtori, C.R.. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacological Research (2001) ; 44 : 183-193 . DOI: 10.1006/phrs.2001.0847 . PMID: 11529685
Traditional Texts
- [13] Grieve, M.. A Modern Herbal. Jonathan Cape / Harcourt Brace (1931)
Pharmacopeias & Reviews
- [14] European Pharmacopoeia Commission. European Pharmacopoeia — Hippocastani semen (Horse Chestnut Seed). Council of Europe / EDQM (2023)
Last updated: 2026-03-02 | Status: review
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.